Trial Profile
A randomised open-labelled multicentre trial of the efficacy of epirubicin, oxaliplatin and capecitabine (EOX) with or without panitumumab in previously untreated advanced oesophago-gastric cancer (REAL3)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 28 Oct 2022
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Capecitabine; Epirubicin; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms REAL3
- 16 Nov 2020 Results assessing the association between EGFR amplification and clinical outcome in patients treated with epirubicin, oxaliplatin and capecitabine plus or minus panitumumab in advanced or locally advanced oesophagogastric Cancer, published in the Gut
- 27 Jul 2020 Status changed from discontinued to completed.
- 11 Oct 2016 Results assessing association between genomic loss of heterozygosity and survival in the REAL3 trial (n=86) presented at the 41st European Society for Medical Oncology Congress